A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Abstract: Despite a recent increase in therapeutic options, patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) eventually require novel therapies. We conducted a phase 1 trial of blinatumomab and lenalidomide in R/R B-NHL. Three dose levels representing 2 schedules were explor...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Joseph M. Tuscano, Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert, Emanual Maverakis, Alexander A. Merleev, Guillaume Luxardi, Mehrdad Abedi, Raghuveer Ranganathan, Dipenkumar Modi, Jasmine Zain, Elizabeth L. Budde, Matthew Mei, Aaron S. Rosenberg, Rasmus T. Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Elad Sharon, Howard Streicher, Alexy Danilov, Edward Newman
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-02-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2473952925007049
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!